Castleark Management LLC lessened its position in shares of Gal�pagos NV (NASDAQ:GLPG) by 31.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,770 shares of the biotechnology company’s stock after selling 3,105 shares during the quarter. Castleark Management LLC’s holdings in Gal�pagos were worth $635,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in GLPG. Financial Gravity Companies Inc. acquired a new position in Gal�pagos in the 4th quarter valued at about $104,000. Tower Research Capital LLC TRC increased its stake in shares of Gal�pagos by 7,340.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,488 shares of the biotechnology company’s stock valued at $140,000 after acquiring an additional 1,468 shares during the last quarter. New York State Common Retirement Fund acquired a new position in shares of Gal�pagos during the 2nd quarter valued at about $166,000. Envestnet Asset Management Inc. increased its stake in shares of Gal�pagos by 156.6% during the 3rd quarter. Envestnet Asset Management Inc. now owns 1,742 shares of the biotechnology company’s stock valued at $177,000 after acquiring an additional 1,063 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Gal�pagos during the 3rd quarter valued at about $218,000. 19.40% of the stock is owned by institutional investors and hedge funds.
A number of brokerages have recently issued reports on GLPG. ValuEngine upgraded Gal�pagos from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. BidaskClub upgraded Gal�pagos from a “hold” rating to a “buy” rating in a report on Wednesday, January 31st. BTIG Research reiterated a “buy” rating and set a $118.00 target price on shares of Gal�pagos in a research note on Thursday, February 8th. Finally, Zacks Investment Research lowered Gal�pagos from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 25th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the stock. Gal�pagos has an average rating of “Hold” and an average target price of $111.00.
Gal�pagos stock traded up $1.44 during mid-day trading on Thursday, hitting $97.94. The company’s stock had a trading volume of 49,560 shares, compared to its average volume of 100,014. The company has a market cap of $5,036.40, a P/E ratio of -37.10 and a beta of 1.95. Gal�pagos NV has a 52-week low of $72.90 and a 52-week high of $121.09.
Gal�pagos (NASDAQ:GLPG) last posted its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.02). Gal�pagos had a negative return on equity of 12.08% and a negative net margin of 74.70%. The firm had revenue of $58.37 million for the quarter, compared to analysts’ expectations of $42.84 million. research analysts forecast that Gal�pagos NV will post -3.91 earnings per share for the current year.
WARNING: This article was originally posted by Macon Daily and is the sole property of of Macon Daily. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://macondaily.com/2018/04/12/castleark-management-llc-has-635000-position-in-galapagos-nv-glpg-updated-updated-updated.html.
Galapagos NV, a clinical-stage biotechnology company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. Its clinical stage programs include filgotinib, which is in Phase III clinical trial for the treatment of rheumatoid arthritis, Crohn's disease, and ulcerative colitis; GLPG1690, which is in Phase IIa clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972, which is in Phase 1 clinical trial for the treatment of osteoarthritis; and MOR106 that is in atopic dermatitis (AtD) patients in Phase Ib trial.
Receive News & Ratings for Gal�pagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gal�pagos and related companies with MarketBeat.com's FREE daily email newsletter.